Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned.
The main question is:
What are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies?
Researchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies.
Participants will:
Complete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes.
Provide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis.
Undergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.
Eligibility criteria
Qualifiers
Age 16 years and above.
Established diagnosis of gender incongruence
Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy
Disqualifiers
Unable to give informed consent
Missing commitment or ability to study protocol adherence
Trial design
Treatments tested in this trial
- Group A (start of GAHT)
- Group B (on-going GAHT)
- Group C (GAS)
Treatment groups
600 Participants
are divided into 3 treatment groupsSponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
University Hospital, Zürich
Collaborator
Cantonal Hospital Lucerne, Switzerland
Collaborator
Source ClinicalTrials.gov